drugset / Trial / NCT00075764

S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

NCT00075764 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using drugs such as anastrozole and fulvestrant may fight breast cancer by blocking the use of estrogen. It is not yet known whether anastrozole is more effective with or without fulvestrant in treating breast cancer. PURPOSE: This randomized phase III trial is studying giving anastrozole together with fulvestrant to see how well it works compared to anastrozole alone as first-line therapy in treating postmenopausal women with metastatic breast cancer.

Timeline

Start
2004-04
Primary completion
2012-12
Completion
2018-10-01

Outcome

Met primary endpoint

registry Arm I Anastrozole vs Arm II Anastrozole and Fulvestrant; p = 0.007; Hazard Ratio (HR) 0.80 (95% CI 0.68 to 0.94); Log Rank NCT00075764 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 1 mg Oral
Subject Fulvestrant Small molecule 250 mg Intramuscular

Indications